

Teneligliptin is non-inferior to sitagliptin for type 2 diabetes (T2DM) inadequately controlled with metformin and glimepiride.

Kim Y, et al. *Diabetes Obes Metab.* **2018** Oct 26.

- To assess the efficacy and safety of add-on therapy with teneligliptin compared with sitagliptin in patients with T2DM inadequately controlled with metformin and glimepiride, a double-blind, non-inferiority study was conducted in 200 Korean subjects with T2DM, with glycated hemoglobin (HbA1c) ranging from 7.0-11.0%, on stable doses of metformin plus glimepiride.
- **There were no significant differences between groups in the proportion of patients achieving HbA1c targets, or changes from baseline in fasting plasma glucose, body weight or lipid levels** at 24 weeks. Rates of adverse events and hypoglycemia were similar.

Teneligliptin was non-inferior to sitagliptin in the context of triple therapy for T2DM and is an important option in this setting.